Howard Brown Health

howardbrown.org

Howard Brown Health Center promotes the well-being of gay, lesbian, bisexual, and transgender (LGBTQ) persons through its health care and wellness programs, including clinical, educational, social service, and research activities. HBHC designed these programs to serve the LGBTQ community in a confidential and supportive environment. HBHC is committed to working cooperatively with other community-based organizations serving the LGBTQ community.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GLOBAL CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET INSIGHTS 2019-2025

Galus | April 14, 2020

news image

Manufacturing process and technology used in CRISPR And CRISPR-Associated (Cas) Genes market, key developments and trends changing in the development Complete examination, including an evaluation of the parent market...

Read More

MEDICAL

NIKANG THERAPEUTICS COMPLETES $200 MILLION SERIES C FINANCING TO ADVANCE HIGHLY DIFFERENTIATED SMALL MOLECULES ADDRESSING DIFFICULT-TO-DRUG TARGETS

NiKang Therapeutics | May 31, 2021

news image

NiKang Therapeutics Inc., a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to assist patients with unmet medical needs; today announced the completion of an oversubscribed $200 million Series C financing led by Cormorant Asset Management, HBM Healthcare Investments, and Octagon Capital Advisors with participation from a premier syndicate of funds, including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Grou...

Read More

MEDTECH, AI

QUANTUM-SI AND BIOVISTA JOIN HANDS TO PROVIDE AI-DRIVEN DEEP PROTEOMICS INSIGHTS

Quantum-Si | January 10, 2023

news image

The leading Protein Sequencing Company™, Quantum-Si, recently announced that it signed a partnership and license agreement with Biovista to offer customers more significant proteomic insights beyond their protein sequence output. Biovista utilizes artificial intelligence in multiple formats to analyze enormous data repositories and visualize non-obvious networks and connections between proteins, diseases, and drug mechanisms of action. The partnership enhances Quantium-Si...

Read More

INDUSTRIAL IMPACT, DIAGNOSTICS

VAXXINITY ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF VXX-401, INVESTIGATIONAL ANTI-PCSK9 VACCINE TO TREAT HYPERCHOLESTEROLEMIA

Vaxxinity, Inc. | March 21, 2023

news image

Vaxxinity, Inc. a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor contributing to heart disease, by targeting proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9). Heart disease remains the leading cau...

Read More
news image

GLOBAL CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET INSIGHTS 2019-2025

Galus | April 14, 2020

Manufacturing process and technology used in CRISPR And CRISPR-Associated (Cas) Genes market, key developments and trends changing in the development Complete examination, including an evaluation of the parent market...

Read More
news image

MEDICAL

NIKANG THERAPEUTICS COMPLETES $200 MILLION SERIES C FINANCING TO ADVANCE HIGHLY DIFFERENTIATED SMALL MOLECULES ADDRESSING DIFFICULT-TO-DRUG TARGETS

NiKang Therapeutics | May 31, 2021

NiKang Therapeutics Inc., a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to assist patients with unmet medical needs; today announced the completion of an oversubscribed $200 million Series C financing led by Cormorant Asset Management, HBM Healthcare Investments, and Octagon Capital Advisors with participation from a premier syndicate of funds, including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Grou...

Read More
news image

MEDTECH, AI

QUANTUM-SI AND BIOVISTA JOIN HANDS TO PROVIDE AI-DRIVEN DEEP PROTEOMICS INSIGHTS

Quantum-Si | January 10, 2023

The leading Protein Sequencing Company™, Quantum-Si, recently announced that it signed a partnership and license agreement with Biovista to offer customers more significant proteomic insights beyond their protein sequence output. Biovista utilizes artificial intelligence in multiple formats to analyze enormous data repositories and visualize non-obvious networks and connections between proteins, diseases, and drug mechanisms of action. The partnership enhances Quantium-Si...

Read More
news image

INDUSTRIAL IMPACT, DIAGNOSTICS

VAXXINITY ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF VXX-401, INVESTIGATIONAL ANTI-PCSK9 VACCINE TO TREAT HYPERCHOLESTEROLEMIA

Vaxxinity, Inc. | March 21, 2023

Vaxxinity, Inc. a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor contributing to heart disease, by targeting proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9). Heart disease remains the leading cau...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us